Cancer Cell International · 2017 · 68 citations · 40 references
MedicineCell BiologyOncologyMolecular OncologyNeuro-oncologyTranscriptomicsBrain TumorsCancer Stem Cell BiologyCancer Stem CellsCancer TranscriptomicsStem Cell TumorigenicityTranscriptomic ProfilingCancer Stem Cell BiomarkersCancer Stem Cell MarkersCancer Stem Cell TranscriptomicsCd133 ExpressionMicroarray AnalysisTranscriptome AnalysisUnsupervised ClusteringWhole Transcriptome Analysis
BACKGROUND: Meningioma tumors arise in arachnoid membranes, and are the most reported central nervous system (CNS) tumors worldwide. Up to 20% of grade I meningioma tumors reoccur and currently predictive cancer stem cells (CSCs) markers for aggressive and drug resistant meningiomas are scarce. METHODS: Meningioma tissues and primary cell lines were investigated using whole transcriptome microarray analysis, immunofluorescence staining of CSCs markers (including CD133, Sox2, Nestin, and Frizzled 9), and drug treatment with cisplatin or etoposide. RESULTS: . Immunofluorescence staining for four tissues confirmed stemness variation in situ. Biological characterization of fifteen meningioma primary cell lines concordantly separated cells into two functionally distinct sub-groups. Pleomorphic cell lines (NG type) grew significantly faster than monomorphic cell lines (G type), had a higher number of cells that express Ki67, and were able to migrate aggressively in vitro. In addition, NG type cell lines had a lower expression of nuclear Caspase-3, and had a significantly higher number of CSCs co-positive for CD133+ Sox2+ or AGR2+ BMI1+. Importantly, these cells were more tolerant to cisplatin and etoposide treatment, showed a lower level of nuclear Caspase-3 in treated cells and harbored drug resistant CSCs. CONCLUSION: Collectively, analyses of tissues and primary cell lines revealed stem cell associated genes as potential targets for aggressive and drug resistant meningiomas.
40
Mechanisms and insights into drug resistance in cancer
Hiba Zahreddine, Katherine L. B. Borden · Frontiers in Pharmacology · 2013 · 660 citations · Full text
Medicine, Oncology, Pharmacology +16
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations
Priscilla K. Brastianos, Peleg Horowitz, Sandro Santagata et al. · Nature Genetics · 2013 · 652 citations · Full text
Oncogenic PI3K mutations are as common as<i>AKT1</i>and<i>SMO</i>mutations in meningioma
Malak Abedalthagafi, Wenya Linda Bi, Ayal A. Aizer et al. · Neuro-Oncology · 2016 · 294 citations · Full text